Sato Noriko, Wu Haitao, Asiedu Kingsley O, Szajek Lawrence P, Griffiths Gary L, Choyke Peter L
From the Molecular Imaging Program, National Cancer Institute (N.S., K.O.A., P.L.C.), Imaging Probe Development Center, National Heart, Lung, and Blood Institute (H.W.), and Positron Emission Tomography Department, Warren Grant Magnuson Clinical Center (L.P.S.), U.S. National Institutes of Health, 10 Center Dr, Bethesda, MD 20892; and Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Md (G.L.G.).
Radiology. 2015 May;275(2):490-500. doi: 10.1148/radiol.15142849. Epub 2015 Feb 20.
PURPOSE: To develop a clinically translatable method of cell labeling with zirconium 89 ((89)Zr) and oxine to track cells with positron emission tomography (PET) in mouse models of cell-based therapy. MATERIALS AND METHODS: This study was approved by the institutional animal care committee. (89)Zr-oxine complex was synthesized in an aqueous solution. Cell labeling conditions were optimized by using EL4 mouse lymphoma cells, and labeling efficiency was examined by using dendritic cells (DCs) (n = 4), naïve (n = 3) and activated (n = 3) cytotoxic T cells (CTLs), and natural killer (NK) (n = 4), bone marrow (n = 4), and EL4 (n = 4) cells. The effect of (89)Zr labeling on cell survival, proliferation, and function were evaluated by using DCs (n = 3) and CTLs (n = 3). Labeled DCs (444-555 kBq/[5 × 10(6)] cells, n = 5) and CTLs (185 kBq/[5 × 10(6)] cells, n = 3) transferred to mice were tracked with microPET/CT. In a melanoma immunotherapy model, tumor targeting and cytotoxic function of labeled CTLs were evaluated with imaging (248.5 kBq/[7.7 × 10(6)] cells, n = 4) and by measuring the tumor size (n = 6). Two-way analysis of variance was used to compare labeling conditions, the Wilcoxon test was used to assess cell survival and proliferation, and Holm-Sidak multiple tests were used to assess tumor growth and perform biodistribution analyses. RESULTS: (89)Zr-oxine complex was synthesized at a mean yield of 97.3% ± 2.8 (standard deviation). It readily labeled cells at room temperature or 4°C in phosphate-buffered saline (labeling efficiency range, 13.0%-43.9%) and was stably retained (83.5% ± 1.8 retention on day 5 in DCs). Labeling did not affect the viability of DCs and CTLs when compared with nonlabeled control mice (P > .05), nor did it affect functionality. (89)Zr-oxine complex enabled extended cell tracking for 7 days. Labeled tumor-specific CTLs accumulated in the tumor (4.6% on day 7) and induced tumor regression (P < .05 on day 7). CONCLUSION: We have developed a (89)Zr-oxine complex cell tracking technique for use with PET that is applicable to a broad range of cell types and could be a valuable tool with which to evaluate various cell-based therapies.
J Nucl Med. 2018-5-4
Pharmaceutics. 2025-4-15
Sci Rep. 2025-7-8
Pharmaceuticals (Basel). 2025-6-15
Commun Eng. 2025-5-15
Pharmaceutics. 2025-4-15
EJNMMI Radiopharm Chem. 2024-11-29
Eur J Nucl Med Mol Imaging. 2015-2
Lancet Oncol. 2014-1
NMR Biomed. 2013-4-22
Cancer Discov. 2013-4-2
N Engl J Med. 2013-3-25
Cancer Lett. 2012-9-27